BR112017008093A2 - processos para tratamento de doenças oculares - Google Patents

processos para tratamento de doenças oculares

Info

Publication number
BR112017008093A2
BR112017008093A2 BR112017008093-1A BR112017008093A BR112017008093A2 BR 112017008093 A2 BR112017008093 A2 BR 112017008093A2 BR 112017008093 A BR112017008093 A BR 112017008093A BR 112017008093 A2 BR112017008093 A2 BR 112017008093A2
Authority
BR
Brazil
Prior art keywords
processes
eye diseases
treating eye
weeks
administering
Prior art date
Application number
BR112017008093-1A
Other languages
English (en)
Inventor
Sallstig Peter
Schmidt Werner
GEKKIEVA Margarita
Warburton James
WEICHSELBERGER Andreas
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54697654&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112017008093(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112017008093A2 publication Critical patent/BR112017008093A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B3/00—Apparatus for testing the eyes; Instruments for examining the eyes
    • A61B3/10—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions
    • A61B3/12—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions for looking at the eye fundus, e.g. ophthalmoscopes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Medical Informatics (AREA)
  • Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

é provido um processo para redução de carga de tratamento para pacientes que têm um distúrbio neovascular intraocular, o processo compreendendo administração de uma quantidade terapeuticamente efetiva de antagonista de vegf em um esquema de dosagem que inclui intervalos de tratamento de 8 e/ou 12 semanas.
BR112017008093-1A 2014-11-07 2015-11-06 processos para tratamento de doenças oculares BR112017008093A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462076770P 2014-11-07 2014-11-07
US62/076,770 2014-11-07
US201462088061P 2014-12-05 2014-12-05
US62/088,061 2014-12-05
PCT/US2015/059575 WO2016073918A1 (en) 2014-11-07 2015-11-06 Methods for treating ocular diseases

Publications (1)

Publication Number Publication Date
BR112017008093A2 true BR112017008093A2 (pt) 2018-03-13

Family

ID=54697654

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112017008093-1A BR112017008093A2 (pt) 2014-11-07 2015-11-06 processos para tratamento de doenças oculares
BR112017008660A BR112017008660A2 (pt) 2014-11-07 2015-11-06 formulação de solução de proteína estável contendo alta concentração de um anticorpo anti-vegf

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR112017008660A BR112017008660A2 (pt) 2014-11-07 2015-11-06 formulação de solução de proteína estável contendo alta concentração de um anticorpo anti-vegf

Country Status (24)

Country Link
US (5) US10689438B2 (pt)
EP (2) EP3215123A1 (pt)
JP (5) JP6753848B2 (pt)
KR (3) KR102588846B1 (pt)
CN (3) CN107635580A (pt)
AU (6) AU2015342815B2 (pt)
BR (2) BR112017008093A2 (pt)
CA (2) CA2966758A1 (pt)
CL (2) CL2017001117A1 (pt)
CO (1) CO2017004596A2 (pt)
EA (1) EA201790989A1 (pt)
EC (1) ECSP17034829A (pt)
GT (1) GT201700096A (pt)
IL (5) IL251642B (pt)
MX (3) MX2017005875A (pt)
MY (2) MY183807A (pt)
NZ (1) NZ730821A (pt)
PE (1) PE20170780A1 (pt)
PH (2) PH12017500843A1 (pt)
RU (1) RU2722643C2 (pt)
SG (3) SG11201702909QA (pt)
TN (1) TN2017000128A1 (pt)
TW (4) TWI806150B (pt)
WO (2) WO2016073915A1 (pt)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110122881A (ko) 2006-04-07 2011-11-11 워너 칠콧 컴퍼니 엘엘씨 인간 단백질 타이로신 포스파타아제 베타(ｈｐｔｐ베타)에 결합하는 항체 및 그의 용도
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
TR201808591T4 (tr) 2008-06-25 2018-07-23 Esbatech Alcon Biomed Res Unit Bir evrensel bir antikor iskeleti kullanılarak tavşan antikorların insanlaştırılması.
BRPI0914319B8 (pt) 2008-06-25 2021-05-25 Esbatech Alcon Biomed Res Unit imunoligante que se liga especificamente ao tnf alfa humano e composição
JP5536113B2 (ja) 2009-07-06 2014-07-02 アケビア セラピューティクス インコーポレイテッド がん細胞の転移を予防するための化合物、組成物および方法
SG10201802789VA (en) 2011-01-13 2018-05-30 Regeneron Pharma Use of a vegf antagonist to treat angiogenic eye disorders
AU2012323856B2 (en) 2011-10-13 2017-05-25 EyePoint Pharmaceuticals, Inc. Methods for treating Vascular Leak Syndrome and cancer
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
JP6483148B2 (ja) 2014-03-14 2019-03-13 エアーピオ セラピューティクス インコーポレイテッド ＨＰＴＰ−β阻害剤
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
TWI806150B (zh) 2014-11-07 2023-06-21 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
RU2699544C2 (ru) 2015-01-28 2019-09-06 Пфайзер Инк. Стабильная водная композиция антитела против фактора роста эндотелия сосудов (VEGF)
US10633433B2 (en) 2015-01-28 2020-04-28 Prothena Biosciences Limited Anti-transthyretin antibodies
US10464999B2 (en) 2015-01-28 2019-11-05 Prothena Biosciences Limited Anti-transthyretin antibodies
US9879080B2 (en) 2015-01-28 2018-01-30 Prothena Biosciences Limited Anti-transthyretin antibodies
CN108290057A (zh) 2015-09-23 2018-07-17 爱尔皮奥治疗有限公司 用tie-2的激活剂治疗眼内压的方法
AU2016381964B2 (en) 2015-12-30 2024-02-15 Kodiak Sciences Inc. Antibodies and conjugates thereof
WO2018017714A1 (en) 2016-07-20 2018-01-25 Aerpio Therapeutics, Inc. HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß)
CN110248674B (zh) * 2016-09-07 2021-10-26 萨辛生命科学有限公司 针对vegf的合成抗体及其用途
US11692027B2 (en) 2016-09-28 2023-07-04 Board Of Regents, The University Of Texas System Antibody and protein therapeutic formulations and uses thereof
MY195529A (en) 2016-11-18 2023-01-30 Astellas Pharma Inc Novel Anti-Human MUC1 Antibody Fab Fragment
US11851659B2 (en) 2017-03-22 2023-12-26 Novartis Ag Compositions and methods for immunooncology
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
WO2018195912A1 (zh) * 2017-04-28 2018-11-01 苏州思坦维生物技术股份有限公司 一种眼用药物组合物及其用途
TWI795415B (zh) 2017-07-07 2023-03-11 日商安斯泰來製藥股份有限公司 新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段
WO2019020777A1 (en) * 2017-07-26 2019-01-31 Formycon Ag LIQUID FORMULATION OF A VEGF ANTAGONIST
CU20200021A7 (es) 2017-10-06 2021-01-12 Prothena Biosciences Ltd Anticuerpos anti-transtiretina
BR112020010483A2 (pt) * 2017-11-29 2020-10-20 Prothena Biosciences Limited formulação liofilizada de um anticorpo monoclonal contra transtirretina
CN111699004A (zh) * 2018-02-06 2020-09-22 豪夫迈·罗氏有限公司 眼科疾病的治疗
EP3765083A1 (en) * 2018-03-16 2021-01-20 Novartis Ag Methods for treating ocular diseases
EP3768706A1 (en) * 2018-03-23 2021-01-27 AbbVie Deutschland GmbH & Co. KG Stable aqueous anti-tau antibody formulations
EP3775267A4 (en) * 2018-04-10 2022-05-18 Askgene Pharma, Inc. NEW DUAL ANTAGONISTS OF VEGF AND ANGIOPOIETIN 2
WO2019217927A1 (en) 2018-05-10 2019-11-14 Regeneron Pharmaceuticals, Inc. High concentration vegf receptor fusion protein containing formulations
US10894824B2 (en) 2018-09-24 2021-01-19 Aerpio Pharmaceuticals, Inc. Multispecific antibodies that target HPTP-β (VE-PTP) and VEGF
AR116566A1 (es) 2018-10-03 2021-05-19 Novartis Ag Administración sostenida de polipéptidos similares a la angiopoyetina 3
SG11202103670XA (en) * 2018-10-10 2021-05-28 Astellas Pharma Inc Pharmaceutical composition containing tagged site-antihuman antibody fab fragment complex
MX2021004774A (es) * 2018-10-29 2021-08-24 Hoffmann La Roche Formulacion de anticuerpos.
CA3119179A1 (en) 2018-11-07 2020-05-14 Applied Molecular Transport Inc. Cholix-derived carriers for oral delivery of heterologous payload
JOP20210152A1 (ar) * 2018-12-18 2023-01-30 Novartis Ag صياغة محلول بروتيني محتوية على تركيز عالٍ من جسم مضاد لـ vegf
CA3129901A1 (en) 2019-02-18 2020-08-27 Eli Lilly And Company Therapeutic antibody formulation
TW202106699A (zh) 2019-04-26 2021-02-16 美商愛德維仁生物科技公司 用於玻璃體內遞送之變異體aav蛋白殼
JP2022530657A (ja) 2019-04-29 2022-06-30 アイポイント ファーマシューティカルズ， インコーポレイテッド シュレム管を標的とするＴｉｅ－２活性化物質
MX2022001975A (es) 2019-08-16 2022-03-11 Applied Molecular Transport Inc Composiciones, formulaciones y produccion y purificacion de interleucinas.
WO2021072265A1 (en) * 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
CN111217834B (zh) 2020-02-21 2021-10-26 维眸生物科技（上海）有限公司 Rock激酶抑制剂的硝基氧衍生物
CN113698478A (zh) * 2020-05-21 2021-11-26 迈威(上海)生物科技股份有限公司 抗α-溶血素的抗体及其稳定制剂
KR20220001106A (ko) * 2020-06-29 2022-01-05 (주)메디톡스 고농도 항-ｖｅｇｆ 항체 제제 및 이에 사용하기 위한 항-ｖｅｇｆ 항체
AU2021308712A1 (en) 2020-07-16 2023-02-02 Novartis Ag Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules
KR20240008821A (ko) * 2021-05-17 2024-01-19 리제너론 파아마슈티컬스, 인크. 혈관신생성 눈 장애 치료를 위한 연장된 고용량 vegf 길항제 요법
CN113940997B (zh) * 2021-12-21 2022-04-08 迈威(上海)生物科技股份有限公司 一种双特异性抗体的稳定制剂
WO2024056058A1 (zh) * 2022-09-16 2024-03-21 齐鲁制药有限公司 一种稳定的高浓度自缓冲药物组合物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EP2319492A3 (en) * 2004-10-21 2011-08-10 Genentech, Inc. Method for treating intraocular neovascular diseases
WO2007011873A2 (en) * 2005-07-15 2007-01-25 Genentech, Inc. Method for treating intraocular neovascular diseases
JP5216002B2 (ja) * 2006-06-16 2013-06-19 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 硝子体内投与に適したｖｅｇｆアンタゴニスト製剤
CA3020290A1 (en) * 2008-06-25 2009-12-30 Esbatech, An Alcon Biomedical Research Unit Llc Stable and soluble antibodies inhibiting vegf
MX344076B (es) 2008-06-30 2016-12-05 Esbatech Alcon Biomed Res Unit Polipeptidos funcionalizados.
SG10201802789VA (en) * 2011-01-13 2018-05-30 Regeneron Pharma Use of a vegf antagonist to treat angiogenic eye disorders
SG194932A1 (en) * 2011-06-30 2013-12-30 Genentech Inc Anti-c-met antibody formulations
UY34404A (es) * 2011-10-20 2013-05-31 Esbatech A Novartis Co Llc Anticuerpo estable unido a múltiples antígenos
UA117466C2 (uk) * 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
WO2015086830A1 (en) * 2013-12-13 2015-06-18 Delenex Therapeutics Ag Skin penetrating polypeptides
TWI806150B (zh) 2014-11-07 2023-06-21 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
US20160144025A1 (en) 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases

Also Published As

Publication number Publication date
RU2017119647A (ru) 2018-12-07
IL283561A (en) 2021-07-29
TW202103735A (zh) 2021-02-01
CL2017001115A1 (es) 2018-01-26
CA2966758A1 (en) 2016-05-12
TWI806150B (zh) 2023-06-21
US11098110B2 (en) 2021-08-24
KR20230066649A (ko) 2023-05-16
AU2020220210B2 (en) 2022-01-20
JP2020193212A (ja) 2020-12-03
AU2018278870A1 (en) 2019-01-03
EP3215123A1 (en) 2017-09-13
EP3215122A1 (en) 2017-09-13
RU2020114917A (ru) 2020-05-22
IL265497B (en) 2021-06-30
PH12017500844B1 (en) 2017-10-30
US20200270336A1 (en) 2020-08-27
ECSP17034829A (es) 2019-02-28
JP2017538674A (ja) 2017-12-28
US10689438B2 (en) 2020-06-23
JP7080263B2 (ja) 2022-06-03
JP2020079242A (ja) 2020-05-28
PH12017500843A1 (en) 2017-10-30
IL283561B (en) 2022-01-01
AU2020220210A1 (en) 2020-10-01
JP6667519B2 (ja) 2020-03-18
KR20170082526A (ko) 2017-07-14
TW201625306A (zh) 2016-07-16
AU2020244614B2 (en) 2023-06-01
TN2017000128A1 (en) 2018-10-19
RU2722643C2 (ru) 2020-06-02
CN114081951A (zh) 2022-02-25
WO2016073918A1 (en) 2016-05-12
US20180298092A1 (en) 2018-10-18
KR102588846B1 (ko) 2023-10-16
JP2017534638A (ja) 2017-11-24
PH12017500844A1 (en) 2017-10-30
NZ730821A (en) 2019-11-29
AU2015342815A1 (en) 2017-05-11
MY183807A (en) 2021-03-16
CO2017004596A2 (es) 2017-08-31
AU2018274882B2 (en) 2020-07-09
IL280087A (en) 2021-03-01
CL2017001117A1 (es) 2018-01-26
TW202146049A (zh) 2021-12-16
RU2020114917A3 (pt) 2022-01-17
US10035850B2 (en) 2018-07-31
IL251642B (en) 2021-02-28
JP6753848B2 (ja) 2020-09-09
CN106999581A (zh) 2017-08-01
TWI705827B (zh) 2020-10-01
SG11201702954XA (en) 2017-05-30
PE20170780A1 (es) 2017-07-04
MY193913A (en) 2022-11-01
WO2016073915A1 (en) 2016-05-12
AU2018278870B2 (en) 2020-05-28
IL265497A (en) 2019-05-30
SG11201702909QA (en) 2017-05-30
CA2966646A1 (en) 2016-05-12
CN107635580A (zh) 2018-01-26
TWI761959B (zh) 2022-04-21
EA201790989A1 (ru) 2017-09-29
IL251696A0 (en) 2017-06-29
SG10201913565RA (en) 2020-02-27
IL251642A0 (en) 2017-06-29
AU2020244614A1 (en) 2020-11-05
US20160130337A1 (en) 2016-05-12
GT201700096A (es) 2019-10-10
RU2017119647A3 (pt) 2019-05-29
MX2017005874A (es) 2017-06-26
MX2021006768A (es) 2021-07-15
IL280087B (en) 2022-02-01
BR112017008660A2 (pt) 2017-12-26
MX2017005875A (es) 2017-06-26
AU2018274882A1 (en) 2018-12-20
TW201625221A (zh) 2016-07-16
US20210340242A1 (en) 2021-11-04
KR20170076781A (ko) 2017-07-04
US20160340420A1 (en) 2016-11-24
AU2015342815B2 (en) 2018-12-13
AU2015342818A1 (en) 2017-05-11
JP2022141923A (ja) 2022-09-29
AU2015342818B2 (en) 2019-01-03
TWI738632B (zh) 2021-09-11

Similar Documents

Publication Publication Date Title
BR112017008093A2 (pt) processos para tratamento de doenças oculares
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
BR112016000546A2 (pt) métodos para tratar ou prevenir condições oftalmológicas
BR112017003546A2 (pt) amidas heterocíclicas como inibidores de rip1 quinase como medicamentos
EA201691872A1 (ru) Гетероциклические соединения для применения в лечении pi3k-гамма-опосредованных расстройств
IL268327A (en) A pharmaceutical preparation for use in the treatment and prevention of c5-related diseases and methods for the treatment and prevention of c5-related diseases
BR112017002637A2 (pt) métodos para tratar ou prevenir condições oftalmológicas
MX2021000538A (es) Uso de sobetirome en el tratamiento de enfermedades de mielinizacion.
MX2017016134A (es) Aril dihidro-2h-benzo[b][1,4]oxazina sulfonamida y compuestos relacionados para uso como agonistas de rory y el tratamiento de enfermedad.
BR112017018964A2 (pt) uso de plinabulin e métodos para tratar tumor cerebral
BR112017003571A2 (pt) terapia combinada
BR112015016282A2 (pt) crenolanibe para tratamento de distúrbios proliferativos de flt3 mutado
EA201791199A1 (ru) Способ лечения болезни альцгеймера
EA201590654A1 (ru) Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона
MA40364A (fr) Polythérapie pour le traitement du cancer
EA201892265A1 (ru) Способы лечения офтальмологических заболеваний
HK1257240A1 (zh) 預防和治療脂肪異常沉積導致的組織損傷的藥物及其用途
BR112019005539A2 (pt) métodos de tratamento de lesão renal aguda
CL2019000625A1 (es) Combinación de agonistas de fxr.
AR104755A1 (es) Método para el tratamiento de enfermedad neurológica
MX2017010654A (es) Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estres.
BR112019004791A2 (pt) tratamento de esclerose múltipla com chs-131
MD20170025A2 (ro) Tratamente terapeutice pe bază de anamorelin
BR112019006174A2 (pt) proteina terapêutica
EA201691656A2 (ru) Терапевтические способы с применением норибогаина и родственных соединений

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]